日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results

Risankizumab治疗中重度斑块状银屑病的长期安全性和有效性：LIMMitless III期开放标签扩展试验的最终结果

期刊:American Journal of Clinical Dermatology
影响因子:8.8
doi:10.1007/s40257-025-00964-6
Papp, Kim A; Lebwohl, Mark G; Puig, Lluís; Ohtsuki, Mamitaro; Beissert, Stefan; Gooderham, Melinda; Amin, Ahmad Z; Wu, Tianshuang; Rubant, Simone; Bialik, Brenton; Ashley, Doug; Soliman, Ahmed M; Chen, Michael M; Blauvelt, Andrew
银屑病
多发性骨髓瘤
发表日期：2025
文献求助 收藏

Correction: Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months

更正：利沙珠单抗治疗中重度银屑病患者的真实世界疗效：VALUE 全球前瞻性上市后观察研究 25 个月中期分析

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-025-01420-3
Thaçi, Diamant; Ohtsuki, Mamitaro; Maul, Julia-Tatjana; Szegedi, Andrea; Luna, Paula C; Lynde, Charles W; Soliman, Ahmed M; Wang, Hongwei; Kaufmann, Christian; Ashley, Doug G; Madihlaba, Tshepiso; Rubant, Simone; Papp, Kim A
银屑病
发表日期：2025
文献求助 收藏

Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study

更正：Risankizumab 对 Secukinumab 或 Ixekizumab 疗效欠佳的银屑病患者的疗效和安全性：一项 3b 期开放标签单臂 (aIMM) 研究的结果

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-024-01328-4
Warren, Richard B; Pavlovsky, Lev; Costanzo, Antonio; Bukhalo, Michael; Korman, Neil J; Huang, Yu-Huei; Kokolakis, Georgios; Pinter, Andreas; Ibrahim, Nadia; Zheng, Yanbing; Drogaris, Leonidas; Stakias, Vassilis; Soliman, Ahmed M; Rubant, Simone; Thaçi, Diamant
银屑病
多发性骨髓瘤
发表日期：2025
文献求助 收藏

Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months

Risankizumab治疗中重度银屑病患者的真实世界疗效：VALUE全球前瞻性上市后观察研究25个月的中期分析

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-025-01342-0
Thaçi, Diamant; Ohtsuki, Mamitaro; Maul, Julia-Tatjana; Szegedi, Andrea; Luna, Paula C; Lynde, Charles W; Soliman, Ahmed M; Wang, Hongwei; Kaufmann, Christian; Ashley, Doug G; Madihlaba, Tshepiso; Rubant, Simone; Papp, Kim A
银屑病
发表日期：2025
文献求助 收藏

Disease severity, treatment patterns, and quality of life in patients with moderate-to-severe psoriasis routinely managed with systemic treatment: results of the CRYSTAL observational study in Central and Eastern European countries

中重度银屑病患者接受系统性治疗后，疾病严重程度、治疗模式和生活质量：CRYSTAL观察性研究在中欧和东欧国家的结果

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2024.1410540
Raam, Liisi; Hartmane, Ilona; Valiukevičienė, Skaidra; Karamova, Arfenya E; Telegdy, Eniko; Botev, Ivan; Marina, Diana; Rubant, Simone; Albuquerque, Teotonio; Constantin, Maria Magdalena
银屑病
发表日期：2024
文献求助 收藏

Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study

Risankizumab治疗对Secukinumab或Ixekizumab疗效欠佳的银屑病患者的疗效和安全性：一项3b期、开放标签、单臂（aIMM）研究的结果

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-024-01292-z
Warren, Richard B; Pavlovsky, Lev; Costanzo, Antonio; Bukhalo, Michael; Korman, Neil J; Huang, Yu-Huei; Kokolakis, Georgios; Pinter, Andreas; Ibrahim, Nadia; Zheng, Yanbing; Drogaris, Leonidas; Stakias, Vassilis; Soliman, Ahmed M; Rubant, Simone; Thaçi, Diamant
银屑病
多发性骨髓瘤
发表日期：2024
文献求助 收藏

Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial

在未接受过系统治疗的中重度斑块状银屑病患者中，利沙珠单抗与富马酸酯的直接比较：一项随机对照试验

期刊:British Journal of Dermatology
影响因子:9.6
doi:10.1111/bjd.20481
Thaçi, D; Eyerich, K; Pinter, A; Sebastian, M; Unnebrink, K; Rubant, S; Williams, D A; Weisenseel, P
银屑病
发表日期：2022
文献求助 收藏

Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up

risankizumab治疗中重度斑块状银屑病的长期疗效和安全性：LIMMitless开放标签扩展试验3年随访期后的中期分析

期刊:British Journal of Dermatology
影响因子:9.6
doi:10.1111/bjd.20595
Papp, K A; Lebwohl, M G; Puig, L; Ohtsuki, M; Beissert, S; Zeng, J; Rubant, S; Sinvhal, R; Zhao, Y; Soliman, A M; Alperovich, G; Leonardi, C
银屑病
多发性骨髓瘤
发表日期：2021
文献求助 收藏

Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study

一项随机、双盲、III期研究显示，阿达木单抗在患有严重慢性斑块状银屑病的儿童患者中具有持续的长期疗效和安全性。

期刊:British Journal of Dermatology
影响因子:9.6
doi:10.1111/bjd.18029
Thaçi, D; Papp, K; Marcoux, D; Weibel, L; Pinter, A; Ghislain, P-D; Landells, I; Hoeger, P H; Unnebrink, K; Seyger, M M B; Williams, D A; Rubant, S; Philipp, S
银屑病
发表日期：2019
文献求助 收藏

Constitutive and functionally relevant expression of JAM-C on platelets

血小板上 JAM-C 的组成和功能相关表达

期刊:Thrombosis and Haemostasis
影响因子:5
doi:10.1160/TH09-08-0572
Luise Erpenbeck, Simone Rubant, Katja Hardt, Sentot Santoso, Wolf-Henning Boehncke, Michael P Schön, Ralf J Ludwig
信号转导
血小板
发表日期：2010
文献求助 收藏